Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
L. Camacho-Arteaga,G. Iacoboni,13 Authors,Antònia Agustí
TLDR
In a cohort study of 172 patients who survived at least 3 months after the CAR T-cell infusion without subsequent antilymphoma therapy, infections and cytopenias were the most common late adverse events after that time point.
Abstract
Key Points Question What is the late safety profile for adult patients with aggressive B-cell non-Hodgkin lymphoma treated with commercially available CD19-targeted chimeric antigen receptor (CAR) T cells? Findings In a cohort study of 172 patients who survived at least 3 months after the CAR T-cell infusion without subsequent antilymphoma therapy, infections and cytopenias were the most common late adverse events after that time point; other late complications included neurologic, cardiovascular, and dermatologic events. Five secondary malignant neoplasms were reported, with no cases of T-cell malignant neoplasms in the patient population. Meaning This study suggests that CAR T-cell therapy has a favorable long-term safety profile.